ArticleFrontiers in immunology2018
Human Properdin Opsonizes Nanoparticles and Triggers a Potent Pro-inflammatory Response by Macrophages without Involving Complement Activation.
Article in Frontiers in immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 36 citations in OpenAlex.
- Unique transcriptomic responses of rat and human alveolar macrophages in an in vitro model of overload with TiOParticle and fibre toxicology · 2025Article
- Expression of Properdin, the positive regulator of the Complement Alternative Pathway, at the fetal-maternal interface in Preeclampsia.Frontiers in immunology · 2025Article
- Nanoparticle-induced systemic toxicity and immune response inFrontiers in pharmacology · 2025Article
- Coupling of Alzheimer's Disease Genetic Risk Factors with Viral Susceptibility and Inflammation.Aging and disease · 2024Review
- Antibodies targeting the glycan cap of Ebola virus glycoprotein are potent inducers of the complement systemCommunications biology · 2024Article
- Infiltrating myeloid cell-derived properdin markedly promotes microglia-mediated neuroinflammation after ischemic stroke.Journal of neuroinflammation · 2023Article
- HBSP improves kidney ischemia-reperfusion injury and promotes repair in properdin deficient miceFrontiers in immunology · 2023Article
- Curcumin and capsaicin regulate apoptosis and alleviate intestinal inflammation induced by Clostridioides difficile in vitro.Annals of clinical microbiology and antimicrobials · 2022Article
- Synthetic Glyconanoparticles Modulate Innate Immunity but Not the Complement System.ACS applied bio materials · 2022Article
- Low molecular weight polysialic acid binds to properdin and reduces the activity of the alternative complement pathway.Scientific reports · 2022Article
- Evolution of complexity in non-viral oligonucleotide delivery systems: from gymnotic delivery through bioconjugates to biomimetic nanoparticles.RNA biology · 2022Review
- CFP is a prognostic biomarker and correlated with immune infiltrates in Gastric Cancer and Lung Cancer.Journal of Cancer · 2021Article
- Human Properdin Released By Infiltrating Neutrophils Can Modulate Influenza A Virus Infection.Frontiers in immunology · 2021Article
- Yogurt Produced by Novel Natural Starter Cultures Improves Gut Epithelial Barrier In Vitro.Microorganisms · 2020Article
- Engineering at the nano-bio interface: harnessing the protein corona towards nanoparticle design and function.The Analyst · 2020Review
- Opsonins and Dysopsonins of Nanoparticles: Facts, Concepts, and Methodological Guidelines.Frontiers in immunology · 2020Review
- Prognostic Value of Complement Properdin in Cancer.Frontiers in immunology · 2020Article
- Nanoparticle-Induced Complement Activation: Implications for Cancer Nanomedicine.Frontiers in immunology · 2020Review
- TSLP Exacerbates Septic Inflammation via Murine Double Minute 2 (MDM2) Signaling Pathway.Journal of clinical medicine · 2019Article
- Comparative in Vitro Cytotoxicity of Realistic Doses of Benchmark Multi-Walled Carbon Nanotubes towards Macrophages and Airway Epithelial Cells.Nanomaterials (Basel, Switzerland) · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 6 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Development of nanoparticles as tissue-specific drug delivery platforms can be considerably influenced by the complement system because of their inherent pro-inflammatory and tumorigenic consequences. The complement activation pathways, and its recognition subcomponents, can modulate clearance of the nanoparticles and subsequent inflammatory response and thus alter the intended translational applications. Here, we report, for the first time, that human properdin, an upregulator of the complement alternative pathway, can opsonize functionalized carbon nanotubes (CNTs)
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.